MedPath

Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy

Not Applicable
Completed
Conditions
Advanced Gastrointestinal Cancer
Interventions
Other: home-based exercise intervention
Registration Number
NCT02677129
Lead Sponsor
Goethe University
Brief Summary

The study is a randomized controlled trial with the aim to examine the feasibility and the effects of a home-based exercise intervention program on activities of daily living (ADL) in patients with advanced gastrointestinal cancer undergoing chemotherapeutic treatment. Further outcomes include functional and body status, quality of life, body composition, and chemotherapy completion rate. Study participants will be randomized to an exercise intervention group or a wait-list control group

Detailed Description

A randomised longitudinal study. A total of 44 gastrointestinal cancer patients before their first-line chemotherapy are recruited and randomised into one of two treatment groups A: Home based- physical activity or B: wait-control. The intervention period is 12 weeks. Primary outcome are the ADLs (iADL 1-8; FIM 1-7).Secondary outcomes are the physical activity, quality of life, peripheral polyneuropathy, chemotherapy regimen, gait speed, postural stability, maximal isometric voluntary force of the upper extremity, Maximal isometric voluntary force (MIVF) and strength endurance of the lower extremity, nutritional state, body composition and perceive functional ability. All measurements are standardized and are performed before chemotherapy, after 2 cycles of chemotherapy (4-6weeks) and after 12 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Histologically classified gastrointestinal cancer
  • UICC III-IV
  • Prior to (planned) first-line chemotherapy (curative und palliative)
  • ≥50 years
Exclusion Criteria
  • ECOG > 2
  • Systemic diseases (MS, ALS)
  • disorders (neurological, skeletal, muscular, mental or cognitive) or drug use (irrespective of the cancer therapy) that may affect gait, balance or muscular strength
  • chronic infection, uncontrolled hypertension (diastolic pressure over 95 mmHg)
  • vestibulopathies
  • uncorrected visual deficits

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
home-based exercise interventionhome-based exercise interventionhome-based exercise intervention: Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
Primary Outcome Measures
NameTimeMethod
Short Physical Performance BatteryChange between the first 12 weeks of chemotherapy

Short battery of physical performance tests used to assess lower extremity function. Balance, gait, strength, and endurance are evaluated.

Secondary Outcome Measures
NameTimeMethod
Postural sway3 times in the course of 12 weeks of chemotherapy

balance measuring (COP) on a capacitive force-measuring platform (30Hz) WinFDM v0.0.41® (Zebris© GmbH, Isny, Germany)

Nutrition Assessment3 times in the course of 12 weeks of chemotherapy

Mini Nutritional Assessment (MNA)

Phase angle3 times in the course of 12 weeks of chemotherapy

multifrequent bioelectrical impedance analysis (DATA-Input) measuring the phase angle

Body cell mass3 times in the course of 12 weeks of chemotherapy

multifrequent bioelectrical impedance analysis (DATA-Input) measuring the body cell mass (BCM)

Perceived functional ability3 times in the course of 12 weeks of chemotherapy

perceived functional ability scale

Quality of life3 times in the course of 12 weeks of chemotherapy

The 36-Items Short Form Health Survey (SF-36)

Polyneuropathy3 times in the course of 12 weeks of chemotherapy

Measuring the sensibility with a Rydel-Seiffer tuning fork

Maximum isometric voluntary force of the lower extremity3 times in the course of 12 weeks of chemotherapy

The maximal isometric voluntary force (MIVF) of the randomly chosen knee extensor is measured with a strain gauge force transducer (ASYS®; SPOREG; 100 Hz) in a standardised seating position (predefined knee and hip angle = 90°).

Gait speed3 times in the course of 12 weeks of chemotherapy

usual gait speed (km/h) on a capacitive force-measuring platform (30Hz) WinFDM v0.0.41® (Zebris© GmbH, Isny, Germany)

Maximum isometric voluntary force of the upper extremity3 times in the course of 12 weeks of chemotherapy

JAMAR Hand Dynamometer

Fat mass3 times in the course of 12 weeks of chemotherapy

multifrequent bioelectrical impedance analysis (DATA-Input) measuring the fat mass

Activities of daily livingChange between the first 12 weeks of chemotherapy

- instrumental Activity of Daily Living (iADL)

Daily physical activity3 times in the course of 12 weeks of chemotherapy

7 days accelerometry

Muscular endurance (Chair-Rise Test)3 times in the course of 12 weeks of chemotherapy

For the five times sit to stand test patients start in a standard position sitting on a chair that is placed next to the wall with the arms folded across their chest. They are asked to stand up from a chair to a full standing position and sit down again keeping the arms crossed for five times as quickly as possible.

Trial Locations

Locations (1)

Agaplesion Markus Hospital

🇩🇪

Frankfurt, Germany

© Copyright 2025. All Rights Reserved by MedPath